Expert Interviews

New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

The liquid biopsy test is approved to identify patients who may benefit from treatment with specific FDA-approved targeted therapies.

The model was found to be superior to the United States Preventive Services Task Force (USPSTF) criteria at identifying African American ever-smokers for lung cancer screening.

The US Oncology expert looks back on how far the ovarian cancer treatment space has come, and where it is headed.

The chief executive officer and co-founder of TrialJectory spoke about the online tool and what it offers for patients, providers, and pharmaceutical companies.

The breast cancer expert discussed research recently published in Cancer Medicine, which suggested that delays in adjuvant chemotherapy are associated with worse survival in this patient population.

The MSK expert discussed how telemedicine may change genetic testing and its access for patients.

The expert from Dana-Farber Cancer Institute spoke about the study of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

The US Oncology expert noted that input of the multidisciplinary board is a great place to air out concerns regarding ovarian cancer treatment.

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

A study published in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients being seen for cancer-related care due to the COVID-19 pandemic.

The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.

Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.

The expert from the Dana-Farber Cancer Institute discussed the study findings which assessed the use of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.

The oncologist from the Morrison Cancer Center explained why he believes the general population should not receive multi-gene panel testing.

The researcher from Quest Diagnostics spoke about a recent study which confirmed the benefit of using liquid-based cytology in cotesting for cervical cancer.

The MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.

The new guidelines suggest the need to phase out cotesting and cytology, shifting towards primary HPV testing starting at age 25 years.

Interim results from the study suggested that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.